ClearOne is trading 5.4% down at $6.97 as investors digest the approved Cortigent reverse-merger and the resulting heavy dilution for existing shareholders.
- The company will pivot from AV/collaboration gear to neurostimulation med-tech, with Vivani Medical expected to own 59–68% of the new Cortigent Holdings entity.
- Legacy ClearOne holders will see their ownership reduced to approximately 13–14%, creating significant downward pressure as terms and timelines become clearer.
- The shift in business focus and equity structure is driving the current sell-off as the market revalues the entity.